Elan Skelaxin FTC investigation

Elan and King Pharmaceuticals are responding to FTC investigation into "Orange Book" patent listings for Elan's muscle relaxant Skelaxin. FTC has "commenced an investigation to determine whether Elan or any other person has engaged in unfair methods of competition with respect to Skelaxin (metaxalone)," Elan says. King says inquiry "raises serious concerns" with respect to its proposed acquisition of Elan ("The Pink Sheet" Feb. 3, p. 29). FTC is also investigating whether Elan restricted generic access to Naprelan (naproxen) ("The Pink Sheet" March 3, p. 37)...